These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21161884)

  • 1. Combination of lithium and duloxetine in 2 depressed patients refractory to duloxetine monotherapy.
    Steffenhagen N; Kürstein B; Kirkby KC; Himmerich H
    Pharmacopsychiatry; 2011 Mar; 44(2):72-4. PubMed ID: 21161884
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy, tolerability, and safety of duloxetine.
    Wise TN
    CNS Spectr; 2005 Dec; 10(12 Suppl 19):10-1. PubMed ID: 18841598
    [No Abstract]   [Full Text] [Related]  

  • 3. Duloxetine: a new serotonin/noradrenaline reuptake inhibitor for the treatment of depression.
    Rabasseda X
    Drugs Today (Barc); 2004 Sep; 40(9):773-90. PubMed ID: 15538550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An open-label study of duloxetine hydrochloride, a mixed serotonin and noradrenaline reuptake inhibitor, in patients with DSM-III-R major depressive disorder. Lilly Duloxetine Depression Study Group.
    Berk M; du Plessis AD; Birkett M; Richardt D
    Int Clin Psychopharmacol; 1997 May; 12(3):137-40. PubMed ID: 9248869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prescribing update: why choose duloxetine for depression?
    Tobin ML
    Issues Ment Health Nurs; 2007 Jan; 28(1):117-20. PubMed ID: 17130011
    [No Abstract]   [Full Text] [Related]  

  • 6. Is there a place for duloxetine?
    Drug Ther Bull; 2007 Apr; 45(4):29-32. PubMed ID: 17451072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serotonin syndrome after discontinuation of olanzapine in a combined treatment with duloxetine -- case report.
    Himmighoffen H; Seifritz E; Boeker H
    Pharmacopsychiatry; 2011 Mar; 44(2):75-6. PubMed ID: 21161885
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of duloxetine on painful physical symptoms associated with depression.
    Goldstein DJ; Lu Y; Detke MJ; Hudson J; Iyengar S; Demitrack MA
    Psychosomatics; 2004; 45(1):17-28. PubMed ID: 14709757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder.
    Schatzberg AF
    J Clin Psychiatry; 2003; 64 Suppl 13():30-7. PubMed ID: 14552654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Duloxetine-associated tardive dyskinesia resolved with fluvoxamine: a case report.
    Albayrak Y; Ekinci O
    J Clin Psychopharmacol; 2012 Oct; 32(5):723-4. PubMed ID: 22926615
    [No Abstract]   [Full Text] [Related]  

  • 11. Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor.
    Westanmo AD; Gayken J; Haight R
    Am J Health Syst Pharm; 2005 Dec; 62(23):2481-90. PubMed ID: 16303903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postictal ventricular tachycardia after electroconvulsive therapy treatment associated with a lithium-duloxetine combination.
    Heinz B; Lorenzo P; Markus R; Holger H; Beatrix R; Erich S; Alain B
    J ECT; 2013 Sep; 29(3):e33-5. PubMed ID: 23670028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical management of depression.
    Malani AK; Ammar H
    N Engl J Med; 2006 Feb; 354(6):646-8; author reply 646-8. PubMed ID: 16470956
    [No Abstract]   [Full Text] [Related]  

  • 14. A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode.
    Martinez JM; Katon W; Greist JH; Kroenke K; Thase ME; Meyers AL; Edwards SE; Marangell LB; Shoemaker S; Swindle R
    Int Clin Psychopharmacol; 2012 Jan; 27(1):17-26. PubMed ID: 22027844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duloxetine in major depressed patients resistant to SSRIs and/or venlafaxine.
    Pitchot W; Scantamburlo G; Ansseau M
    Psychiatr Danub; 2010 Nov; 22 Suppl 1():S106-7. PubMed ID: 21057413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder.
    Thase ME; Pritchett YL; Ossanna MJ; Swindle RW; Xu J; Detke MJ
    J Clin Psychopharmacol; 2007 Dec; 27(6):672-6. PubMed ID: 18004135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.
    Nierenberg AA; Greist JH; Mallinckrodt CH; Prakash A; Sambunaris A; Tollefson GD; Wohlreich MM
    Curr Med Res Opin; 2007 Feb; 23(2):401-16. PubMed ID: 17288694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland.
    Benedict A; Arellano J; De Cock E; Baird J
    J Affect Disord; 2010 Jan; 120(1-3):94-104. PubMed ID: 19497623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful duloxetine use to prevent venlafaxine withdrawal symptoms.
    Hsiao MC; Liu CY
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):576. PubMed ID: 17889418
    [No Abstract]   [Full Text] [Related]  

  • 20. Duloxetine hydrochloride.
    Waitekus AB; Kirkpatrick P
    Nat Rev Drug Discov; 2004 Nov; 3(11):907-8. PubMed ID: 15558861
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.